1984
Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience.
Tester W, Kinsella T, Waller B, Makuch R, Kelley P, Glatstein E, DeVita V. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. Journal Of Clinical Oncology 1984, 2: 762-9. PMID: 6547479, DOI: 10.1200/jco.1984.2.7.762.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsHodgkin's diseaseMalignant neoplasmsSolid tumorsNational Cancer Institute ExperienceChronic myeloid leukemiaCases of sarcomaRisk of leukemiaUntreated patientsPatient ageHodgkin's lymphomaMedical recordsInstitute experienceMyeloid leukemiaSimilar riskAge 40Treatment groupsPatientsGreater riskLeukemiaTen yearsDiseaseTumorsLymphomaPositive association
1982
Undifferentiated non‐Hodgkin'S lymphomas (Burkitt's and non‐Burkitt's types). The relevance of making this histologic distinction
Miliauskas J, Berard C, Young R, Garvin A, Edwards B, Devita V. Undifferentiated non‐Hodgkin'S lymphomas (Burkitt's and non‐Burkitt's types). The relevance of making this histologic distinction. Cancer 1982, 50: 2115-2121. PMID: 7127252, DOI: 10.1002/1097-0142(19821115)50:10<2115::aid-cncr2820501024>3.0.co;2-9.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaMedian ageStage IVPrimary siteHistologic distinctionIntra-abdominal involvementFive-year survivalNational Cancer InstituteMedian survivalBurkitt's typeRetrospective studyHodgkin's lymphomaPatient populationLonger survivalCancer InstituteLymphomaPatientsSurvivalDiseaseMonthsAgePresentationYearsCases
1980
The Rappaport classification of non-Hodgkin's lymphomas: a closer look using other proposed classifications.
Garvin A, Simon R, Young R, DeVita V, Berard C. The Rappaport classification of non-Hodgkin's lymphomas: a closer look using other proposed classifications. Seminars In Oncology 1980, 7: 234-43. PMID: 6998002.Peer-Reviewed Original ResearchConceptsLukes-Collins systemNon-Hodgkin's lymphomaLukes-CollinsClassification of non-Hodgkin's lymphomasClinical management of patientsAggressive combination chemotherapyDiffuse histiocytic lymphomaHomogeneous group of patientsManagement of patientsGroup of patientsB symptomsLymphocytic lymphomaCentroblastic-centrocyticCombination chemotherapyDiffuse lymphomaLymphoblastic lymphomaPlasmacytoid differentiationKiel classificationRappaport classificationNodular lymphomaHistiocytic lymphomaRetrospective reviewFollicular patternClinicopathologic entityYounger patientsThe evolution of primary multimodality treatment in resectable breast cancer
Henney J, Devita V. The evolution of primary multimodality treatment in resectable breast cancer. Cancer 1980, 46: 999-1008. PMID: 6994877, DOI: 10.1002/1097-0142(19800815)46:4+<999::aid-cncr2820461325>3.0.co;2-e.Peer-Reviewed Original ResearchConceptsDisease-free intervalPremenopausal womenClinical trialsBreast cancerProspective randomized clinical trialsStage II breast cancerAdjuvant therapy studiesResectable breast cancerRandomized clinical trialsNational Cancer InstitutePositive resultsPostmenopausal womenMultimodality treatmentPostoperative periodPrognostic factorsNational mortalityClinical dataEstrogen receptorDrug doseCancer InstituteStage IClinical researchPatientsTherapy studiesTrials
1976
Pathological staging of 100 consecutive untreated patients with non‐Hodgkin's lymphomas. Extramedullary sites of disease
Lotz M, Chabner B, Devita V, Johnson R, Berard C. Pathological staging of 100 consecutive untreated patients with non‐Hodgkin's lymphomas. Extramedullary sites of disease. Cancer 1976, 37: 266-270. PMID: 1247961, DOI: 10.1002/1097-0142(197601)37:1<266::aid-cncr2820370136>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsPathological stagingHodgkin's lymphomaNodular lymphomaHepatic biopsyDiffuse lymphomaFirst positive biopsyPercutaneous hepatic biopsyConsecutive untreated patientsBone marrow needle biopsyNegative spleensAbdominal involvementExploratory laparotomyUntreated patientsHepatic involvementWedge biopsyHistologic typeOverall incidenceRappaport classificationAbdominal diseasePositive biopsiesExtramedullary sitesNeedle biopsyUntreated casesPatientsBiopsy
1973
Combined drug treatment of Hodgkin's disease: remission induction, remission duration, and survival; an appraisal.
DeVita V. Combined drug treatment of Hodgkin's disease: remission induction, remission duration, and survival; an appraisal. National Cancer Institute Monograph 1973, 36: 373-9. PMID: 4744596.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntineoplastic AgentsBiopsyCarmustineChlorambucilCyclophosphamideDactinomycinDrug Therapy, CombinationEvaluation Studies as TopicFollow-Up StudiesHodgkin DiseaseHumansMechlorethamineMiddle AgedPrednisoneProcarbazineRemission, SpontaneousTime FactorsVinblastineVincristine
1972
A decade of combination chemotherapy of advanced Hodgkin's disease
Devita V, Canellos G, Moxley J. A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer 1972, 30: 1495-1504. PMID: 4565815, DOI: 10.1002/1097-0142(197212)30:6<1495::aid-cncr2820300613>3.0.co;2-i.Peer-Reviewed Original ResearchConceptsAdvanced Hodgkin's diseaseComplete remission rateHodgkin's diseaseRemission rateRemission durationCombination chemotherapySingle agentLonger disease-free intervalDisease-free intervalAcute childhood leukemiaNew treatment programCombination of drugsComplete remissionComplete respondersCooperative trialsStage IIIChildhood leukemiaEffective drugsTreatment programTherapyUse of combinationsDiseasePilot studyFurther treatmentRemission
1971
Anergy and tryptophan metabolism in Hodgkin’s disease
DeVita V, Chabner B, Livingston D, Oliverio V. Anergy and tryptophan metabolism in Hodgkin’s disease. American Journal Of Clinical Nutrition 1971, 24: 835-840. PMID: 5091524, DOI: 10.1093/ajcn/24.7.835.Peer-Reviewed Original Research